CD70 and neoplasm: While detailed ovarian-specific preclinical results from this trial are still emerging, broader early-phase data show that CD70 CAR T-cells can induce meaningful anti-tumor activity in solid malignancies, and the therapy is being refined with strategies like allogeneic “off-the-shelf” constructs and safety switches (e.g., TCR or CD52 knockouts and safety mimotopes) to mitigate toxicity and improve access.